References
- 1. G. A. McClelland, R. J. Stubbs, J. A. Fix, S. A. Pogany and G. M. Zentner, Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reducase inhibitor efficacy through administration of a controlled porosity osmotic pump dosage form, Pharm. Res. 8 (1991) 873–876; https://doi.org/10.1023/A:101589932810510.1023/A:1015899328105
- 2. A. A. Anshuman, K. R. Mahadik and A. Paradkar, Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: In vitro and in vivo evaluations, Pharm. Res. 22 (2005) 990–998; https://doi.org/10.1007/s11095-005-4594-z10.1007/s11095-005-4594-z15948043
- 3. M. Schachter, Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update, Fundam. Clin. Pharmacol. 19 (2005) 117–125; https://doi.org/10.1111/j.1472-8206.2004.00299.x10.1111/j.1472-8206.2004.00299.x15660968
- 4. A. Fattahi, J. Karimi-Sabet, A. Keshavarz, A. Golzary, M. Rafiee-Tehrani and F. A. Dorkoosh, Preparation and characterization of simvastatin nanoparticles using rapid expansion of supercritical solution (RESS) with trifluoromethane, J. Supercrit. Fluids107 (2016) 469–478; https://doi.org/10.1016/j.supflu.2015.05.01310.1016/j.supflu.2015.05.013
- 5. J. K. Patel and V. B. Sutariya, Micronisation of simvastatin by the supercritical antisolvent technique: in vitro-in vivo evaluation, J. Microencapsul. 32 (2015) 193–200; https://doi.org/10.3109/02652048.2014.99572610.3109/02652048.2014.99572625535989
- 6. P. A. Sonar, A. L. Behera, S. K. Banerjee, D. D. Gaikwad and S. L. Harer, Preparation and characterization of simvastatin solid dispersion using skimmed milk, Drug Dev. Ind. Pharm. 41 (2015) 22–27; https://doi.org/10.3109/03639045.2013.84583610.3109/03639045.2013.84583624160569
- 7. K. M. Hosny, A. Khames and S. S. A. Elhady, Preparation and evaluation of orodispersible tablets containing hydroxylbutyl-beta-cyclodextrin-simvastatin solid dispersion, Trop. J. Pharm. Res. 12 (2013) 469–476; https://doi.org/10.4314/tjpr.v12i4.410.4314/tjpr.v12i4.4
- 8. S. D. Saoji, V. S. Belgamwar, S. S. Dharashivkar, A. A. Rode, C. Mack and V. S. Dave, The study of the influence of formulation and process variables on the functional attributes of simvastatin-phospholipid complex, J. Pharm. Innov.11 (2016) 264–278; https://doi.org/10.1007/s12247-016-9256-710.1007/s12247-016-9256-7
- 9. G. Abdelbary, M. Amin and S. Salah, Self nano-emulsifying simvastatin based tablets: design and in vitro/in vivo evaluation, Pharm. Dev. Technol.18 (2013) 1294–1304; https://doi.org/10.3109/10837450.2012.67298910.3109/10837450.2012.67298922468935
- 10. Z. W. Zhang, H. H. Bu, Z. W. Gao, Y. Huang, F. Gao and Y. P. Li, The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats, Int. J. Pharm. 394 (2010) 147–153; https://doi.org/10.1016/j.ijpharm.2010.04.03910.1016/j.ijpharm.2010.04.03920435111
- 11. B. K. Kang, J. S. Lee, S. K. Chon, S. Y. Jeong, S. H. Yuk, G. Khang, H. B. Lee and S. H. Cho, Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs, Int. J. Pharm. 274 (2004) 65–73; https://doi.org/10.1016/j.ijpharm.2003.12.02810.1016/j.ijpharm.2003.12.028
- 12. A. Porfire, D. Muntean, M. Achim, L. Vlase and I. Tomuta, Simultaneous quantification of simvastatin and excipients in liposomes using near infrared spectroscopy and chemometry, J. Pharm. Biomed. Anal.107 (2015) 40–49; https://doi.org/10.1016/j.jpba.2014.12.01310.1016/j.jpba.2014.12.013
- 13. V. J. Stella and Q. He, Cyclodextrins, Toxicol. Pathol.36 (2008) 30–42; https://doi.org/10.1177/019262330731094510.1177/0192623307310945
- 14. J. Pitha, J. Milecki, H. Fales, L. Pannell and K. Uekama, Hydroxypropyl-β-cyclodextrin: preparation and characterization; effect on solubility of drugs, Int. J. Pharm. 29 (1986) 73–82; https://doi.org/10.1016/0378-5173(86)90201-210.1016/0378-5173(86)90201-2
- 15. C. Jullian, Improvement of galangin solubility using native and derivative cyclodextrin. An UV-vis and NMR study, J. Chil. Chem. Soc.54 (2009) 201–203; https://doi.org/10.4067/S0717-9707200900020002510.4067/S0717-97072009000200025
- 16. Y. Kwon, H. Kim, S. Park and S. Jung, Enhancement of solubility and antioxidant activity of some flavonoids based on the inclusion complexation with sulfobutylether beta-cyclodextrin, Bull. Korean Chem. Soc. 31 (2010) 3035–3037; https://doi.org/10.5012/bkcs.2010.31.10.303510.5012/bkcs.2010.31.10.3035
- 17. X. H. Wen, Z. Y. Liu and T. Q. Zhu, Mass spectrometry and molecular modeling studies on the inclusion complexes between α, β-cyclodextrins and simvastatin, Chem. Phys. Lett.405 (2005) 114–117; https://doi.org/10.1016/j.cplett.2005.01.10310.1016/j.cplett.2005.01.103
- 18. F. Csempesz, A. Süle and I. Puskás, Induced surface activity of supramolecular cyclodextrin-statin complexes: Relevance in drug delivery, Coll. Surf. A.354 (2010) 308–313; https://doi.org/10.1016/j.colsurfa.2009.09.00810.1016/j.colsurfa.2009.09.008
- 19. S. W. Jun, M. S. Kim, J. S. Kim, H. J. Park, S. Lee, J. S. Woo and S. J. Hwang, Preparation and characterization of simvastatin/hydroxylpropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process, Eur. J. Pharm. Biopharm. 66 (2007) 413–421; https://doi.org/10.1016/j.ejpb.2006.11.01310.1016/j.ejpb.2006.11.01317240129
- 20. L. X. Zhang, Y. X. Zhang, L. Zhang and Y. H. Chen, Preparation of simvastatin orally disintegrating tablets and its quality evaluation, Chin. J. New Drugs17 (2008) 766–768; https://doi.org/10.3321/j.issn:1003-3734.2008.09.013
- 21. T. Higuchi and K. A. Connors, Phase solubility techniques, Adv. Anal. Chem. Instrum. 4 (1965) 117–212.
- 22. C. Mendes, A. Buttchevitz, J. H. Kruger, J. M. Kratz, C. M. O. Simoes, P. D. Benedet, P. R. Oliveira and M. A. S. Silva, Inclusion complexes of hydrochlorothiazide and beta-cyclodextrin: Physicochemical characteristics, in vitro and in vivo studies, Eur. J. Pharm. Sci.83 (2016) 71–78; https://doi.org/10.1016/j.ejps.2015.12.01510.1016/j.ejps.2015.12.01526687444
- 23. Y. M. Liu, X. F. Wang and D. Wang, Preparation and pharmacokinetics in rats of simvastatin solid lipid nanoparticles, Chin. Pharmacist. 19 (2016) 50–53; https://doi.org/10.3969/j.issn.1008-049X.2016.01.014
- 24. L. Tan, L. L. Yang, X. Zhang, Y. S. Yuan and S. S. Ling, Determination of simvastatin in human plasma by high performance liquid chromatography, Chin. J. Chromatogr. 18 (2000) 232–234; https://doi.org/10.3321/j.issn:1000-8713.2000.03.010
- 25. F. Ungaro, C. Giovino, O. Catanzano, A. Miro, A. Mele, F. Quaglia and M. I. La Rotonda, Use of cyclodextrins as solubilizing agents for simvastatin: Effect of hydroxylpropyl-β-cyclodextrin on lactone/hydroxyacid aqueous equilibrium, Int. J. Pharm. 404 (2011) 49–56. https://doi.org/10.1016/j.ijpharm.2010.10.05010.1016/j.ijpharm.2010.10.050
- 26. M. Yamamoto, F. Hirayama and K. Uekama, Improvement of stability and dissolusion of prostaglandin E1 by maltosyl-β-cyclodexrtin in lyophilized formulation, Chem. Pharm. Bull. 40 (1992) 747–751; https://doi.org/10.1248/cpb.40.74710.1248/cpb.40.747
- 27. A. Sule, L. Szente and F. Csempesz, Enhancement of drug solubility in supramolecular and colloidal systems, J. Pharm. Sci. 98 (2009) 484–494; https://doi.org/10.1002/jps.2143710.1002/jps.21437
- 28. M. J. Arias, J. R. Moyano and J. M. Ginés, Investigation of the triamterene-β-cyclodextrin system prepared by co-grinding, Int. J. Pharm.153 (1997) 181–189; https://doi.org/10.1016/S0378-5173(97)00101-410.1016/S0378-5173(97)00101-4